Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use ...

Pfizer and BioNTech said on Friday that a committee from the European Medicine Agency recommended marketing authorization for its Omicron adapted vaccine to prevent Covid-19, meaning the vaccine is ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted ...

While Australia's therapeutic goods regulator is evaluating two new vaccines targeting the JN.1 strain of COVID-19, the ...

Respiratory illnesses like influenza, COVID-19 and Respiratory Syncytial Virus (RSV) are known to spread more rapidly during ...

With the U.S. Food and Drug Administration and Centers for Disease Control and Prevention approval of new mRNA COVID-19 ...

Chaffee County, CO - Chaffee County Public Health (CCPH) has been preparing for another active respiratory illness season and ...

Two new COVID-19 strains are circulating globally. Here's what we know about them and what experts anticipate.

The monovalent XBB.1.5 COVID-19 vaccine is effective against XBB and JN lineage hospitalization; however, protection against the latter may be attenuated.

Targeting the KP.2 strain is expected to provide better protection against COVID-19 based on current data. The 2024-2025 mRNA COVID-19 vaccines will include a monovalent component that corresponds to ...